Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF vs G-CSF for Stem Cell Mobilization in Lymphoma
NCT05970185Phase 1Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim in lymphoma (2 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Total CD34+ cell yield. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05970185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970185.